Most Read Articles
Roshini Claire Anthony, 6 days ago

Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia. 

Elvira Manzano, 5 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
2 days ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.

Nivolumab exceeds standard 5-year survival in NSCLC in CheckMate 003

Pearl Toh
11 Apr 2017

Non-small cell lung cancer (NSCLC) patients treated with the immune checkpoint inhibitor nivolumab showed a 16 percent 5-year overall survival (OS) rate, according to long-term follow-up data of the CheckMate 003* study presented at the American Association for Cancer Research Annual Meeting 2017 (AACR 2017) held recently in Washington, DC, US. 

“The 5-year overall survival rate reported in this study is much higher than what is reported for this population of patients receiving standard-of-care treatment,” according to Dr Julie Brahmer from Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, US. “Statistics show that most patients with advanced disease die within a year of diagnosis, and the [historical] 5-year survival rate for metastatic NSCLC is about 4 percent.”

The phase Ib dose-escalation expansion study randomized 129 advanced NSCLC patients, who were previously treated with one to five lines of systemic regimens, to receive nivolumab at either 1, 3, or 10 mg/kg Q2W in 8-week cycles for up to 96 weeks of treatment or until disease progression or intolerance to toxicity. They were followed for at least 58 months. [AACR 2017, abstract CT077]

The Kaplan-Meier analysis estimated the 5-year OS rate to be 16 percent (95 percent confidence interval [CI], 10–23) in the overall study population. Specifically, similar OS rates were seen in patients with squamous (n=54; 16 percent, 95 percent CI, 8–28) and nonsquamous (n=74; 15 percent, 95 percent CI, 8–25) NSCLC.

Of the 16 patients (median age 61.5 years, nine males) who survived for at least 5 years, 12 patients did not require further therapy after stopping nivolumab at 96 weeks and remained progression-free for at least 5 years.   

“A small subset of NSCLC patients appear to respond to nivolumab and have beaten the odds that most patients with this cancer face,” said Brahmer. “Our study results show that for a small subset of patients, immunotherapy can work for a very long time.”

Sixty-eight patients whose tumour samples were available for PD-L1 staining showed varying survival rates with different PD-L1 expression levels: the estimated 5-year OS was 20 percent for those with <1 percent PD-L1 expression (n=30), 23 percent for those with ≥1 percent expression (n=38), and 43 percent among those with ≥50 percent PD-L1 expression (n=13).

“We saw improved survival across all PD-L1 staining,” said Brahmer, who attributed the nonsignificant difference between the three groups to the small patient number in each subgroup.

“It’s clear that the patients who beat the survival odds are in some ways truly unique biologically, and the goal now is to discover exactly how immunotherapy is keeping their disease in check,” said Brahmer.

Thus far, the researchers were unable to identify any factors linked to long-term survival within the 16 survivors, who did not appear to differ from the overall study population in terms of clinical, demographic, and biological features.

“Now, we need to figure out how to make more patients responsive to immunotherapy by exploring combinations of immunotherapy drugs and other treatment agents,” Brahmer suggested.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia. 

Elvira Manzano, 5 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
2 days ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.